Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia

AIMS: In previous randomized controlled trials, the use of tolvaptan (TLV) at a fixed dose of 30 mg/day for 1 year did not provide renal benefits in patients with heart failure (HF). This retrospective, cohort study examined the renoprotective effects of long‐term, flexible‐dose, and lower‐dose TLV...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Tatsufumi, Hamano, Takayuki, Ohtani, Tomohito, Doi, Yohei, Shimada, Karin, Matsumoto, Ayumi, Yamaguchi, Satoshi, Hashimoto, Nobuhiro, Senda, Masamitsu, Sakaguchi, Yusuke, Matsui, Isao, Nakamoto, Kei, Sera, Fusako, Hikoso, Shungo, Sakata, Yasushi, Isaka, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712924/
https://www.ncbi.nlm.nih.gov/pubmed/34554640
http://dx.doi.org/10.1002/ehf2.13507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712924/
https://www.ncbi.nlm.nih.gov/pubmed/34554640
http://dx.doi.org/10.1002/ehf2.13507

Ejemplares similares